Trial · NCT00624338
Results by group21
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 21
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Experiencing a New Flare as Defined by British Isles Lupus Assessment Group (BILAG) Score A or B | Atacicept 75 mg | 57.32 | percentage of participants | ||
| Percentage of Participants Experiencing a New Flare as Defined by British Isles Lupus Assessment Group (BILAG) Score A or B | Atacicept 150 mg | 36.11 | percentage of participants | ||
| Percentage of Participants Experiencing a New Flare as Defined by British Isles Lupus Assessment Group (BILAG) Score A or B | Placebo | 53.25 | percentage of participants | ||
| Time to First New Flare as Defined by BILAG Score A or B | Atacicept 75 mg | 143 | 95% Confidence Interval 112 to 226 | days | |
| Time to First New Flare as Defined by BILAG Score A or B | Atacicept 150 mg | 310 | 95% Confidence Interval 169 to NA | days | |
| Time to First New Flare as Defined by BILAG Score A or B | Placebo | 142 | 95% Confidence Interval 87 to 197 | days | |
| Percentage of Participants Experiencing a New Flare as Defined by BILAG Score A or B During Initial 24 Weeks | Atacicept 75 mg | 40.13 | percentage of participants | ||
| Percentage of Participants Experiencing a New Flare as Defined by BILAG Score A or B During Initial 24 Weeks | Atacicept 150 mg | 28.47 | percentage of participants | ||
| Percentage of Participants Experiencing a New Flare as Defined by BILAG Score A or B During Initial 24 Weeks | Placebo | 35.06 | percentage of participants | ||
| Percentage of Participants Within Ordinal Response Categories for British Isles Lupus Assessment Group (BILAG) Flares | Atacicept 75 mg | No BILAG A, no BILAG B, and completed treatment | 52.3 | percentage of participants | |
| Percentage of Participants Within Ordinal Response Categories for British Isles Lupus Assessment Group (BILAG) Flares | Atacicept 150 mg | No BILAG A, no BILAG B, and completed treatment | 60.5 | percentage of participants | |
| Percentage of Participants Within Ordinal Response Categories for British Isles Lupus Assessment Group (BILAG) Flares | Placebo | No BILAG A, no BILAG B, and completed treatment | 52.9 | percentage of participants | |
| Percentage of Participants Within Ordinal Response Categories for British Isles Lupus Assessment Group (BILAG) Flares | Atacicept 75 mg | No BILAG A, at least 1 BILAG B in treatment period | 39.8 | percentage of participants | |
| Percentage of Participants Within Ordinal Response Categories for British Isles Lupus Assessment Group (BILAG) Flares | Atacicept 150 mg | No BILAG A, at least 1 BILAG B in treatment period | 28.9 | percentage of participants | |
| Percentage of Participants Within Ordinal Response Categories for British Isles Lupus Assessment Group (BILAG) Flares | Placebo | No BILAG A, at least 1 BILAG B in treatment period | 38.2 | percentage of participants | |
| Percentage of Participants Within Ordinal Response Categories for British Isles Lupus Assessment Group (BILAG) Flares | Atacicept 75 mg | At least 1 BILAG A in treatment period | 7.8 | percentage of participants | |
| Percentage of Participants Within Ordinal Response Categories for British Isles Lupus Assessment Group (BILAG) Flares | Atacicept 150 mg | At least 1 BILAG A in treatment period | 10.5 | percentage of participants | |
| Percentage of Participants Within Ordinal Response Categories for British Isles Lupus Assessment Group (BILAG) Flares | Placebo | At least 1 BILAG A in treatment period | 8.8 | percentage of participants | |
| Mean Cumulative Corticosteroid Dose | Atacicept 75 mg | 2456.79 | Standard Deviation 1029.87 | mg | |
| Mean Cumulative Corticosteroid Dose | Atacicept 150 mg | 2018.87 | Standard Deviation 1062.61 | mg |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00624338/results